Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ethinyl estradiol
Drug ID BADD_D00844
Description Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability.[A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.[A191107] Ethinylestradiol was granted FDA approval on 25 June 1943.[L11884]
Indications and Usage Ethinylestradiol is combined with other drugs for use as a contraceptive, premenstrual dysphoric disorder, moderate acne, moderate to severe vasomotor symptoms of menopause, prevention of postmenopausal osteoporosis.[L11944,L11965,L11947,L11950,L11845,L9806,L11953,L10304,L11956,L11959,L11962]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00977
KEGG ID D00554
MeSH ID D004997
PubChem ID 5991
TTD Drug ID D06NXY
NDC Product Code 63190-0620; 44132-010; 65089-0044; 12860-0463; 22552-0034; 44132-002; 60870-0463
UNII 423D2T571U
Synonyms Ethinyl Estradiol | Estradiol, Ethinyl | Ethynyl Estradiol | Estradiol, Ethynyl | Ethinyloestradiol | 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)- | Ethinyl Estradiol Hemihydrate | Hemihydrate, Ethinyl Estradiol | Ethinyl Estradiol, (8 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer | Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer | Progynon C | Microfollin | Microfollin Forte | Ethinyl-Oestradiol Effik | Ethinyl Oestradiol Effik | Ethinylestradiol Jenapharm | Jenapharm, Ethinylestradiol | Lynoral | Estinyl | Ethinyl Estradiol, (9 beta,17 alpha)-Isomer
Chemical Information
Molecular Formula C20H24O2
CAS Registry Number 57-63-6
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=C3C=CC(=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abortion18.01.01.001---
Abortion spontaneous18.01.04.001---
Acne23.02.01.001---
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anxiety19.06.02.002--
Apathy19.04.04.002---
Application site erythema08.02.01.001; 12.07.01.001; 23.03.06.005---
Application site pain08.02.01.004; 12.07.01.004---
Application site rash08.02.01.016; 12.07.01.016; 23.03.13.008---
Application site reaction08.02.01.006; 12.07.01.006---
Benign hepatic neoplasm09.04.01.001; 16.06.01.001---
Breast discharge21.05.05.001---
Breast enlargement21.05.04.001---
Breast pain21.05.05.003--
Breast tenderness21.05.05.004---
Budd-Chiari syndrome09.01.06.001; 24.01.03.001--
Carbohydrate tolerance decreased13.02.02.003---
Cataract06.06.01.001--
Cerebral haemorrhage17.08.01.003; 24.07.04.001---
Cerebral thrombosis17.08.01.006; 24.01.04.003---
Cerebrovascular accident17.08.01.007; 24.03.05.001--
Cervical discharge21.06.01.001---
Cervix carcinoma16.12.01.001; 21.06.02.001---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chloasma18.08.02.002; 23.05.01.001---
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene